HRT for Menopause?

Thisarticle I saw on Yahoo News is an example of why patients ought not to go scouring the Internet for all their medical information.  The title of the article "Doctors Clear Up Confusion Over Hormone Therapy" is rather misleading.  Hormone replacement therapy (i.e. supplement estrogen and progesterone pills) has long been known to be the best intervention for refractory menopausal symptoms.  Unfortunately, a Women's Health Initiative study from a decade ago demonstrated that subsets of post-menopausal of women who took hormonal replacement therapy (HRT) medication increased their risk of developing breast cancer by 25%.  Afterwards, enthusiasm for HRT sort of tapered off.  As you could imagine.  This new statement avers that:...while the therapy comes with risks, its benefits generally outweigh the harm for women under age 60, or those who've been in menopause for fewer than 10 years. The increased risk ofbreast cancer also appears to disappear a few years after treatment is stopped......doctors recommend low doses of HRT for women whosemenopausal symptoms are limited to vaginal dryness and pain during intercourse. HRT is not recommended for women who've had breast cancer So if you're under 60, have had symptoms less than 10 years, never had breast cancer, and your symptoms are limited to vaginal dryness and dyspareunia, then HRT is for you.  I'm a little wary myself.  Curiously absent from the ...
Source: Buckeye Surgeon - Category: Surgery Authors: Source Type: blogs

Related Links:

FDA head Dr. Scott Gottlieb today released a statement warning about “vaginal rejuvenation” procedures intended to treat conditions related to menopause, urinary incontinence or sexual function, saying that the products used in the procedures “don’t have adequate evidence to support their use for this purpose.” Gottliebb said that the procedures use lasers or energy-based devices to destroy or reshape vaginal tissue, and while the FDA has approved such devices for treating serious conditions such as the destruction of abnormal or precancerous cervical or vaginal tissues, the devices and proced...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Women's Health Alma Lasers Cynosure Inc. InMode Aesthetic Solutions sciton Source Type: news
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion Regardless of menopausal status, women reported high occurrence rates for several menopausal symptoms. Associations between some symptom occurrence rates and menopausal status depended on the patients' age. Implications for Practice As part of a preoperative symptom assessment, clinicians need to consider a woman's menopausal status and salient demographic and clinical characteristics. The identification of women with a higher symptom burden will assist with more effective management.
Source: Cancer Nursing - Category: Nursing Tags: Articles Source Type: research
ConclusionsWhile QoL in disease-free breast cancer survivors 5  years post-diagnosis was largely comparable to the general population on average, still many survivors suffered from adverse effects. There appears to be a need for ongoing screening and support regarding fatigue, sleep problems, cognitive problems, arthralgia/pain, menopausal/sexual symptoms, phy sical performance, and weight problems during and several years following breast cancer therapy.
Source: Quality of Life Research - Category: Health Management Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
CONCLUSIONS: While some menopausal-related symptom clusters were consistent across time and dimensions, the majority of symptoms clustered together differently depending on whether they were evaluated prior to or at 12 months after breast cancer surgery. An increased understanding of how symptom clusters change over time may assist clinicians to focus their symptom assessments and management strategies. PMID: 29353634 [PubMed - in process]
Source: European Journal of Oncology Nursing - Category: Nursing Authors: Tags: Eur J Oncol Nurs Source Type: research
Approximately 60% to 100% of women with breast cancer experience at least one menopausal-related symptom. Little is known about associations between menopausal status and symptoms in women 12 months after breast cancer surgery.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Tags: Original Article Source Type: research
Abstract BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breast canc...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
This study, the first to examine potential adverse health effects in users of vaginal estrogen compared with non-users, suggests that vaginal estrogen therapy is a safe treatment for genitourinary symptoms such as burning, discomfort, and pain during intercourse associated with menopause.AUTHORSThe paper ’s authors are Dr. Carolyn Crandall of UCLA; Kathleen Hovey of the State University of New York at Buffalo; Christopher Andrews of the University of Michigan; Dr. Rowan Chlebowski of City of Hope; Marcia Stefanick of Stanford University; Dr. Dorothy Lane of the State University of New York at Ston y Brook; Dr. Jan Sh...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
ConclusionsThis review established a set of evidence-based predictors that can be used to help identify women at higher risk of experiencing distress following completion of primary breast cancer treatment.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: American Medical Association (AMA) | Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Internet | Men | Menopause | Pain | Study | Surgeons | Women